Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

[1]  T. Merigan,et al.  Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. , 1999, Circulation.

[2]  J. Squifflet,et al.  Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. , 1999, The New England journal of medicine.

[3]  M. Mach,et al.  Strain-Specific Neutralization of Human Cytomegalovirus Isolates by Human Sera , 1999, Journal of Virology.

[4]  P. Ljungman,et al.  Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. , 1998, Transplantation.

[5]  H. Einsele,et al.  Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. , 1998, The Journal of infectious diseases.

[6]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[7]  M. Boeckh,et al.  Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. , 1997, Blood.

[8]  J. Niland,et al.  Evaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients , 1997, Journal of clinical microbiology.

[9]  C. Schmidt,et al.  The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. , 1997, The Journal of infectious diseases.

[10]  M. Boeckh,et al.  Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.

[11]  T. Stevens-Ayers,et al.  Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence , 1996, Journal of clinical microbiology.

[12]  S. Riddell.  Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts. , 1995, Seminars in respiratory infections.

[13]  A. Nademanee,et al.  Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up. , 1995, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  K. Wittkowski,et al.  Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. , 1995, Blood.

[15]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[16]  M. Pepe,et al.  Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. , 1994, Blood.

[17]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.

[18]  S. Hammer,et al.  Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation , 1993, Annals of Internal Medicine.

[19]  J. Meyers,et al.  Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. , 1991, The New England journal of medicine.

[20]  J. Meyers,et al.  Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. , 1991, The Journal of infectious diseases.

[21]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[22]  H. Tilg,et al.  Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. , 1991, The Journal of infectious diseases.

[23]  H. Schran,et al.  PHASE I STUDY OF SAFETY AND PHARMACOKINETICS OF A HUMAN ANTICYTOMEGALOVIRUS MONOCLONAL ANTIBODY IN ALLOGENEIC BONE MARROW TRANSPLANT RECIPIENTS , 1991, Transplantation.

[24]  R. Pollard,et al.  Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication. , 1991, Antiviral research.

[25]  F. Lakeman,et al.  In vitro neutralization of Cytomegalovirus (CMV) strains by a human monoclonal antibody, MSL-109 , 1991 .

[26]  A. Nademanee,et al.  Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. , 1988, Transplantation.

[27]  D. Stover,et al.  Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. , 1988, Annals of internal medicine.

[28]  E. Reed,et al.  Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. , 1988, Annals of internal medicine.

[29]  E. J. Wilson,et al.  The protective effects of hyperimmune anti-murine cytomegalovirus antiserum against lethal viral challenge: the case for passive-active immunization. , 1986, Clinical immunology and immunopathology.

[30]  D. Snydman,et al.  Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. , 1983, Annals of internal medicine.

[31]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[32]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[33]  H. Deeg,et al.  Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. , 1997, Blood.

[34]  W. Britt,et al.  Human cytomegalovirus glycoproteins. , 1996, Intervirology.